'Bcr abl' presentation slideshows

Disease-Specific Treatment of Relapse after Allogeneic Transplantation

Disease-Specific Treatment of Relapse after Allogeneic Transplantation. Treatment of Relapse. Cellular Immunotherapy Withdrawal of immune suppression DLI ( + chemotherapy) Second allogeneic SCT Non-Cellular therapies Supportive care Conventional chemotherapy or radiation

1.63k views • 141 slides

??????????

??????????. ???????? ???. ????????. ???????? ???????? ????????????. ????????. ??( gene)? ????????????? RNA ??????????? ???( oncogene)? ????????????????????????????????? ????????? ??? ????? ???? ????( tumor suppressor genes)? ????????????????????????????????????. ????????.

1.37k views • 105 slides

Mechanisms of Mutagenesis & Carcinogenesis

Mechanisms of Mutagenesis & Carcinogenesis. Jamil Momand, Ph.D. California State University at Los Angeles. Outline (in brief). Introduction Carcinogenesis - a definition Pathways to cancer: overview Oncogenes Tumor suppressor genes Apoptosis Telomerase Angiogenesis Summary.

1.01k views • 62 slides

Molecular Pathology and the Molecular Diagnostics Lab

3.3k views • 61 slides

856 views • 53 slides

Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia. CML. Philadelphia Chromosome. Philadelphia Chromosome Translocation in CML Results in BCR-ABL Oncogene. 9. 9q+. Ph 22q-. Stem cell disorder Characterized by myeloproliferation Well-described clinical course. 22. Translocation. BCR ABL. BCR. ABL.

1.22k views • 52 slides

Objectives

Biologic Targeting in RT Bill McBride Dept. Radiation Oncology David Geffen School Medicine UCLA, Los Angeles, Ca. wmcbride@mednet.ucla.edu. Objectives. Understand the relationship between molecular carcinogenesis and radiation response Know how to target receptor tyrosine kinases

618 views • 51 slides

White Blood Cell Disease

National Taiwan University Hospital Department of Internal Medicine Division of Hematology ???. White Blood Cell Disease. Non-malignant Disorder of Leukocyte . 1.Variations of leukocytes in disease 2.Neutropenia 3.Qualitative disorder of leukocytes

708 views • 47 slides

RATs

539 views • 31 slides

Large- scale shRNA screens to identify novel combination therapies for the treatment of cancer

Large- scale shRNA screens to identify novel combination therapies for the treatment of cancer. Mark A. Gregory, Ph.D Research Instructor DeGregori Lab. BIOS 6660. BIOS 6660 Lecture: shRNA synthetic lethal screening Overview: Biological problem: Chronic Myeloid Leukemia (CML)

430 views • 30 slides

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia. CML. CML :Chronic Myeloid Leukemia - Summary -. Clonal myeloproliferative disorder of pluripotent stem cells ? proliferation, ?apoptosis ,defective adhesion Cytogenetic hallmark: Ph chromosome Molecular hallmark: BCR/ABL BCR/ABL initiation-causative event in CML.

810 views • 27 slides

R5 ??? SUPERVISOR ?????

R5 ??? SUPERVISOR ?????. Breast Cancer. The most prevalent cancer in female Mortality 4 th in Taiwan. Treatment of Breast Cancer. Breast Cancer. When to change regimen? Unacceptable toxicity Progression disease. Current Tools for Follow-up. Radiologic image Standard serologic test

418 views • 27 slides

524 views • 20 slides

Philadelphia Chromosome

1.07k views • 19 slides

What is RNA interference? Shooting down mRNA

What is RNA interference? Shooting down mRNA. RNAi. Background What is it? Why use it? The mechanism and process. Plasmid Virus. Jorgensen 1990 van der Krol 1990. Gene injection (pigmentation Enzyme-petunias) Expectation: more red color Co-suppression of transgene

419 views • 19 slides

Identification and RQ-PCR monitoring of CML patients with rare variant BCR-ABL transcripts

Identification and RQ-PCR monitoring of CML patients with rare variant BCR-ABL transcripts. Chris Bowles West Midlands Regional Genetics Laboratory. Chris Bowles WMRGL. Chronic Myeloid Leukaemia. Chronic Myeloid Leukaemia is a stem cell cancer representing about 15-20% of adult leukaemia.

422 views • 18 slides

Biologically-Based Estimates of Radiation-Induced CML Risk

Biologically-Based Estimates of Radiation-Induced CML Risk. Tom Radivoyevitch Assistant Professor Epidemiology and Biostatistics Case Western Reserve University Email: txr24@case.edu Website: http://epbi-radivot.cwru.edu/. Linear Risk Model. Using the BCR - ABL to CML

253 views • 15 slides

Tyrosine Kinase inhibitors

Tyrosine Kinase inhibitors. Presented BY : Group 5, PharmD . Supervised by : Dr. Nashaat. Imatinib resistance. Resistance to imatinib is still a problem ,mainly in patients in the accelerated Or blast crisis phases of the disease.

1.51k views • 12 slides

U08023 MERTK AL049381 PBX1 U33017 SLAM Z15108 PRKCZ AB014555 KIAA0655

Y09443 AGPS D31762 TRAM-like protein AF001601 Paraoxonase2 M55531 SLC2A5 D88153 HYA22 U26455 ATM U07563 ABL U60519 CASP10 U84388 CRADD J03040 SPARC. U08023 MERTK AL049381 PBX1 U33017 SLAM

118 views • 1 slides

Supplemental Fig. 2

Supplemental Fig. 2. a. 32Dp210. 32DP210. f. 32Dp210. g. 32Dp210. WP1193 ( m M) C 0.5 1.0 2.0 3.0 4.0. e. 32DP210. c. d. K562-R. C 15 30 45 60 (min).

97 views • 1 slides